Outlook Therapeutics says newly FDA-approved LYTENAVA will be its key entry into ophthalmology. CEO Bob Jahr called the drug a new growth platform for retina disease and broader vision health.
published
Outlook Therapeutics says newly FDA-approved LYTENAVA will be its key entry into ophthalmology. CEO Bob Jahr called the drug a new growth platform for retina disease and broader vision health.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.